Morgan Stanley's analyst Ricky Goldwasser maintains an Underweight rating on Bright Health Gr (NYSE:BHG), indicating a bearish outlook. However, the price target has been raised from $2 to $160, which could create some short-term uncertainty. The impact on the stock price is neutral in the short term as the rating remains unchanged, but the increased price target may generate some interest.